Title: Science Research Article – S-4 Andarine Research Overview | Research Studies
S-4 Andarine Research Overview
What Is S-4 Andarine?
S-4 Andarine is a non-steroidal selective androgen receptor modulator investigated in controlled laboratory and preclinical models involving androgen-receptor signalling, tissue-selective activity, skeletal-muscle endpoints, bone-density measurements and body-composition variables.
The compound is commonly identified by several names, including S-4, Andarine and GTx-007. These names describe the same research compound and should not be confused with S-1, S-22 Ostarine or S-23.
S-4 belongs to the arylpropionamide class of non-steroidal androgen-receptor ligands. Its development formed part of wider research into compounds capable of activating androgen-receptor pathways differently across separate tissues.
The principal molecular characteristics of S-4 Andarine include:
Compound name—S-4 Andarine, Alternative name—GTx-007, Chemical class—Non-steroidal arylpropionamide, Research classification—Selective androgen receptor modulator, Molecular formula—C₁₉H₁₈F₃N₃O₆, Approximate molecular weight—441.36 g/mol, CAS number—401900-40-1, Primary research target—Androgen receptor.
S-4 is considered a genuine SARM because its principal research mechanism involves androgen-receptor modulation. This distinguishes it from compounds such as MK-677 Ibutamoren, SR-9009 and SR-9011, which are frequently included within commercial SARMs categories despite operating through different molecular targets.
Researchers searching for S-4 Andarine UK, S-4 for sale UK, Andarine for sale or where to buy S-4 should understand its correct classification. It is an androgen-receptor research compound rather than a peptide, steroid hormone, growth-hormone secretagogue or REV-ERB agonist.
The central scientific question surrounding S-4 is not simply whether it activates the androgen receptor. Researchers are also interested in how its activity varies according to tissue, cellular environment, receptor co-regulators, concentration and selected experimental endpoint.
This S-4 Andarine research overview examines its chemical identity, androgen-receptor mechanism, tissue-selectivity research, principal experimental endpoints, analytical requirements and current evidence limitations.
How S-4 Andarine Works in Research
The androgen receptor is a ligand-activated nuclear receptor involved in the regulation of androgen-responsive gene expression.
In an inactive state, androgen receptors are located principally within the cellular interior and associated with chaperone proteins. When a suitable ligand binds to the receptor, several coordinated events may occur.
These events can include:
Ligand binding, Receptor conformational change, Reorganisation of chaperone proteins, Movement of the receptor towards the nucleus, Interaction with androgen-response elements, Recruitment of transcriptional co-regulators, Changes in androgen-responsive gene expression.
S-4 is investigated as a non-steroidal androgen-receptor ligand. Its molecular structure differs substantially from testosterone, dihydrotestosterone and other steroidal androgens, even though these compounds can interact with the same receptor system.
This distinction matters because the chemical structure of a ligand can influence the receptor conformation produced after binding. Different receptor conformations may recruit different combinations of co-activators and co-repressors.
The resulting transcriptional response can therefore vary across cell types and tissues. This concept contributes to the proposed tissue selectivity of SARMs.
S-4 has been investigated as an androgen-receptor agonist or partial agonist, depending on the model and selected endpoint. Describing it as universally producing one fixed level of receptor activation would oversimplify its experimental behaviour.
Researchers may examine S-4 using:
Androgen-receptor reporter assays, Receptor-binding experiments, Competitive ligand assays, Nuclear-translocation imaging, Gene-expression analysis, Protein-expression measurements, Receptor-antagonist controls, Concentration-response studies, Time-dependent exposure designs, Comparative androgen-receptor panels.
Reporter assays can measure whether androgen-receptor activation corresponds with a detectable transcriptional signal. Competitive binding experiments may examine how strongly S-4 interacts with the receptor relative to other ligands.
Gene-expression measurements can help researchers examine downstream responses. These may include changes in androgen-responsive transcription, structural proteins, metabolic enzymes and tissue-associated molecular markers.
However, receptor binding and functional activation are not identical measurements.
A compound may bind strongly to a receptor while producing different degrees of transcriptional activity according to the cellular environment. Likewise, a response observed in one reporter system may not occur identically in another cell type.
S-4 research should therefore combine receptor-binding measurements with functional endpoints whenever possible.
What Does Tissue Selectivity Mean for S-4?
The term selective androgen receptor modulator refers to a compound investigated for differential androgen-receptor activity across tissues.
Selectivity does not mean that the compound acts only in one tissue. It also does not mean the complete absence of activity in other androgen-responsive systems.
Instead, tissue selectivity describes a relative difference between responses observed across separate experimental environments.
Early SARM research sought compounds capable of supporting androgen-receptor-associated activity in skeletal and muscular models while producing a different activity profile in selected reproductive tissues.
Preclinical investigations reported that S-4 displayed stronger agonist-like activity in some anabolic tissues than in certain androgenic tissues. These findings helped establish S-4 as an important early example of a tissue-selective androgen-receptor modulator.
Several mechanisms may contribute to tissue-selective behaviour:
Differences in androgen-receptor concentration, Variation in transcriptional co-activators, Variation in transcriptional co-repressors, Differences in local enzyme expression, Distinct receptor conformations, Differences in ligand metabolism, Tissue-specific gene accessibility, Variation in compound exposure and distribution.
Steroidal androgens can also be modified by enzymes such as 5α-reductase and aromatase. Non-steroidal SARMs have different structural and metabolic characteristics, which can contribute to a different tissue-response profile.
However, tissue selectivity is always relative and model-dependent.
A compound described as selective in one experimental comparison may produce a different result when the concentration, tissue, exposure duration or measured endpoint changes. Researchers should not treat the word “selective” as a guarantee of activity limited to one biological system.
What Researchers Study S-4 Andarine For
S-4 Andarine has been investigated principally through preclinical models examining androgen-receptor signalling and tissue-associated responses.
Principal S-4 research areas include:
Androgen-receptor binding, Tissue-selective receptor activation, Skeletal-muscle markers, Muscle-mass measurements, Strength-associated endpoints, Bone mineral density, Bone mineral content, Bone-strength variables, Body-composition measurements, Adiposity measures, Gene-expression responses, Metabolism and compound detection.
Much of the foundational evidence surrounding S-4 comes from controlled animal models involving altered androgen environments. These models allow researchers to compare untreated groups, reference-androgen groups and different S-4 exposure conditions.
The findings can help researchers investigate whether S-4 produces concentration-dependent activity and whether its response differs across muscle, bone and reproductive-tissue measurements.
Results from these models remain preclinical. They should not be converted into guaranteed outcomes, personal-use recommendations or general performance claims.
S-4 and Skeletal-Muscle Research
Skeletal-muscle research involving S-4 has examined variables including tissue mass, lean-tissue measurements, muscle strength and androgen-responsive gene expression.
Muscle mass and muscle strength should be treated as separate endpoints.
An increase in measured tissue mass does not automatically establish a proportional change in functional strength. Strength measurements can also be influenced by fibre composition, neurological activation, experimental technique and baseline condition.
Relevant skeletal-muscle measurements include:
Individual muscle weight, Lean-tissue measurements, Grip-strength variables, Isolated muscle force, Muscle-fibre diameter, Protein-expression markers, Androgen-receptor expression, Transcriptional responses, Myogenic signalling variables.
A robust experimental design should compare molecular, structural and functional measurements rather than relying on one endpoint.
The selected model is also important. Responses in a model with experimentally reduced androgen signalling may differ from responses in material with an unaltered baseline environment.
S-4 and Bone Research
S-4 has also been investigated in bone-related research models.
Published preclinical studies examined bone mineral density, bone mineral content, bone strength and whether SARM exposure influenced changes caused by experimentally altered endocrine signalling.
Bone-research measurements may include:
Whole-body bone mineral density, Trabecular bone measurements, Cortical bone measurements, Bone mineral content, Mechanical strength testing, Bone-turnover markers, Histomorphometric analysis, Osteoblast-associated variables, Osteoclast-associated variables.
Bone mineral density provides useful structural information, but it does not independently describe every aspect of bone quality. Mineral distribution, microarchitecture, cortical thickness and mechanical strength can also affect experimental interpretation.
Studies reporting S-4-associated changes in bone measurements therefore provide evidence within the particular models tested. They do not establish universal effects outside those conditions.
S-4 and Body-Composition Variables
Some S-4 research has examined lean-tissue, fat-mass and total body-composition measurements.
These endpoints may be assessed using dual-energy X-ray absorptiometry, tissue weighing, imaging, biochemical analysis or controlled metabolic measurements.
Body-composition data can be influenced by:
Baseline endocrine conditions, Energy intake, Activity level, Fluid distribution, Experimental duration, Age of the model, Selected concentration, Measurement method, Calibration and operator technique.
A reported change in one body-composition measurement should not be presented without describing the model and comparison group.
The strongest wording is that S-4 has been investigated in preclinical models involving lean-tissue and adiposity measurements. This is more scientifically accurate than converting the findings into promotional body-transformation claims.
How S-4 Differs From Steroidal Androgens
S-4 is a non-steroidal small molecule. It does not share the fused four-ring steroid structure associated with testosterone and related steroidal compounds.
Both S-4 and steroidal androgens can interact with the androgen receptor, but their chemical structures, metabolism and receptor-associated behaviour differ.
Relevant distinctions include:
S-4 is non-steroidal, S-4 belongs to the arylpropionamide class, It does not require a steroid backbone to bind the androgen receptor, Its receptor conformation may recruit different co-regulators, Its metabolism differs from that of steroidal androgens, Its tissue-selectivity profile is relative and experimentally defined.
Researchers should not describe S-4 as an anabolic steroid. It is more accurately classified as a non-steroidal selective androgen receptor modulator.
However, being non-steroidal does not mean that the compound is biologically inactive or separated from every wider androgen-receptor-associated response.
The correct distinction concerns chemical class and experimental behaviour—not an assumption of activity limited to one pathway or tissue.
S-4, Andarine and GTx-007 Naming
Correct naming is particularly important when researching or buying S-4 in the UK.
The principal recognised terms are:
S-4, S4, Andarine, GTx-007, GTx007.
These names may appear with inconsistent punctuation across product listings, research papers and analytical databases.
S-4 should not be confused with:
S-1, another early arylpropionamide SARM, S-22, commonly associated with Ostarine or Enobosarm, S-23, a separate investigational SARM, SR-9009, a REV-ERB agonist research compound, SR-9011, a related REV-ERB agonist research compound.
Correct naming supports reliable literature searches and helps prevent analytical or product-selection errors.
Researchers searching for Andarine UK or S-4 Andarine for sale should check the CAS number, molecular formula, molecular weight and supporting analytical documentation.
A product labelled only as “S4” without a defined identity may be difficult to distinguish from incorrectly named or incompletely documented material.
How Researchers Identify and Analyse S-4
Analytical identity is particularly important within the SARMs market because published investigations have reported problems involving inaccurate labels, undeclared ingredients and differences between advertised and detected compounds.
S-4 can be examined using several complementary analytical methods.
HPLC may be used to evaluate chromatographic purity and identify the proportion of detected material associated with the principal peak.
Liquid chromatography–mass spectrometry can help examine molecular identity and distinguish S-4 from related compounds, contaminants and degradation products.
Nuclear magnetic resonance spectroscopy may provide more detailed structural confirmation when required.
Relevant analytical information includes:
Compound name, CAS number, Molecular formula, Expected molecular mass, Chromatographic purity, Mass-spectrometry identity, Batch or lot number, Manufacturing date, Storage conditions, Certificate of analysis, Capsule-content consistency.
Purity and identity are not the same measurement.
A chromatogram showing one dominant peak may suggest high chromatographic purity, but additional analysis is required to establish that the peak represents S-4 Andarine.
For capsule products, researchers may also examine content uniformity. This determines whether the declared quantity of S-4 is distributed consistently across the tested capsules.
What Should Researchers Check When Buying S-4 Andarine in the UK?
Researchers searching for S-4 for sale UK, Andarine for sale UK, buy S-4 UK or where to buy Andarine should assess more than price and capsule quantity.
The supplier should clearly identify the material as S-4 Andarine and provide a consistent technical specification.
Researchers should check:
Correct compound name, Alternative names such as Andarine or GTx-007, CAS number, Molecular formula, Molecular weight, Declared capsule strength, Number of capsules, Purity documentation, Identity testing, Batch information, UK manufacturing or encapsulation information, Storage guidance, Research-use classification, Supplier business details.
The BioPlex S-4 Andarine research product contains 50 capsules with a declared strength of 15mg per capsule and is supplied for controlled laboratory and analytical research.
Researchers comparing SARMs for sale UK should not assume that all websites use the same sourcing, encapsulation, analytical or documentation standards.
Supplier transparency can include registered business information, batch traceability, accessible terms, contact details and clear explanations of how the product is manufactured and verified.
Commercial search phrases such as buy S-4 UK or Andarine for sale may help researchers locate potential suppliers, but they should never replace technical evaluation.
Limitations of Current S-4 Research
S-4 has a meaningful history within early SARM research, but the evidence base has important limitations.
Much of the frequently cited research is preclinical. The available literature does not provide the same depth of controlled evidence available for established, approved compounds.
Important limitations include:
Heavy reliance on animal models, Differences between experimental systems, Limited advanced controlled trial evidence, Variation in concentration and exposure duration, Incomplete long-term characterisation, Differences between laboratory material and online products, Potential confusion between S-4 and related SARMs, Reliance on selected surrogate endpoints, Limited independent replication of some findings.
Results involving bone, muscle or body-composition measurements should always be interpreted within the conditions tested.
Researchers should also separate evidence about the correctly identified S-4 molecule from claims made about commercial products. A published study using characterised research material does not verify the identity or purity of every product advertised as Andarine.
This distinction makes batch-specific analytical documentation especially important.
Conclusion
S-4 Andarine, also known as GTx-007, is a non-steroidal selective androgen receptor modulator studied for tissue-dependent androgen-receptor activity.
Its molecular formula is C₁₉H₁₈F₃N₃O₆, its approximate molecular weight is 441.36 g/mol and its CAS number is 401900-40-1.
Preclinical studies have investigated S-4 in relation to skeletal-muscle variables, bone mineral density, bone strength, body composition and androgen-responsive tissue measurements.
These studies contributed to the wider development of tissue-selective androgen receptor modulators. However, selectivity remains relative and depends on the model, concentration, tissue, receptor environment and measured endpoint.
S-4 should be classified as a genuine SARM because it acts through androgen-receptor modulation. It should not be confused with Ostarine S-22, S-23, MK-677, SR-9009 or other compounds commonly displayed within the wider SARMs market.
Researchers considering S-4 Andarine UK products should examine chemical identity, capsule strength, batch documentation, chromatographic purity, mass-spectrometry evidence and supplier transparency.
The available evidence supports continued laboratory and preclinical investigation. It does not justify guaranteed outcomes, personal-use guidance or claims that S-4 produces identical effects across every experimental environment.
Continue Exploring...
Explore S-4 Andarine Research Capsules ⟶
Explore the BioPlex SARMs Research Collection ⟶
Read the Complete SARMs UK Research Compound Guide ⟶
Read Why MK-677 Ibutamoren Is Not a Genuine SARM ⟶
Learn More About BioPlex Peptides ⟶
All discussion is presented strictly for educational and scientific research purposes only, supporting informed study, data interpretation, and responsible laboratory investigation.
